In this episode our host Dr Sarah Drummond speaks with Professor Catherine Smith and Dr Andrew Pink about eczema therapeutics:

• The use of JAK inhibitors licensed for use in managing eczema including their mechanism of action, monitoring requirements and potential side effects.
• Newer agents currently under investigation.
• The BEACON trial

Recorded: 19 March 2024

For more information, visit: www.stjohnsdermacademy.com/podcasts

Disclaimer: The information on our podcasts is based on the latest evidence and expert opinion at the time of recording. The information is for general purposes only and we cannot offer advice for specific patients. Equally, this information is geared towards healthcare professionals. Any member of the public or patients listening should not use this as advice to treat their own condition or others and should consult their own physician for any medical needs they may have.

In this episode our host Dr Sarah Drummond speaks with Professor Catherine Smith and Dr Andrew Pink about eczema therapeutics:

• Where conventional systemic agents fit within the evolving landscape of eczema therapeutics.
• The biologic agents licensed for use in eczema including their mechanism of action, monitoring requirements and potential side effects.

Recorded: 19 March 2024

For more information, visit: www.stjohnsdermacademy.com/podcasts

Disclaimer: The information on our podcasts is based on the latest evidence and expert opinion at the time of recording. The information is for general purposes only and we cannot offer advice for specific patients. Equally, this information is geared towards healthcare professionals. Any member of the public or patients listening should not use this as advice to treat their own condition or others and should consult their own physician for any medical needs they may have.

In this episode our host Dr Sarah Drummond speaks with Dr Thomas Tull about pemphigus vulgaris:

• The clinical features of pemphigus vulgaris and other variants of pemphigus.
• The step-wise management of pemphigus vulgaris including an approach to managing severe disease and the use of rituximab and intravenous immunoglobulin .

Resources and further reading:
• British Association of Dermatologists’ guidelines for the management of pemphigus vulgaris, 2017 (https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.15930)
• European guidelines for the management of pemphigus vulgaris and foliaceous initiated by the European Academy of Dermatology and Venereology, 2020 (https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.16752)
• Rituximab and Covid-19 Risk – a single-centre cohort study (https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(23)00004-8/fulltext)
• Phase 2 Study of efficacy and safety of Rilzabrutinib for patients with pemphigus vulgaris (https://pubmed.ncbi.nlm.nih.gov/35686647/)
• Phase 2 Study of the use of Efgartigimod for patients with pemphigus vulgaris and foliaceous (https://pubmed.ncbi.nlm.nih.gov/34608631/)

Disclosure: Dr. Tull provides consultancy services for Argenx who market Efgartigimod, which has been referenced in Part 1 and 2 of this series.

Recorded date: 26 January 2024